And, pending approval, Zymeworks is eligible to receive tiered royalties between 10% and 20% on Jazz’s net sales. Zanidatamab is an HER2-targeted bispecific antibody with multiple novel ...
MADISON, Wis., December 03, 2024--(BUSINESS WIRE)--Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific ...
Invenra Inc. is pleased to announce the launch of its Rapid Bispecific Antibody Discovery Services. Utilizing Invenra’s B-Body® Bispecific Platform, the streamlined service can identify ...
(NASDAQ:APVO), a clinical-stage biotechnology company focused on developing novel immune-oncology therapeutics based on its proprietary ADAPTIR ® and ADAPTIR-FLEX ® platform technologies, today ...
Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for the treatment of solid tumors ...
HAYWARD, Calif.--(BUSINESS WIRE)--Rondo Therapeutics, a privately held biopharmaceutical immuno-oncology company pioneering the development of next-generation T cell-engaging bispecific antibodies for ...